01778nas a2200313   4500000000100000008004100001260001700042653001200059653003200071653002300103653003100126653001600157653001600173653001100189653001200200653001100212653000900223653001800232653003200250653002600282100001600308700001700324700002400341245009600365300001000461490000700471520097200478022001401450       2006                            d  c2006 May-Jul10aAnimals10aBacterial Typing Techniques10aBacterial Vaccines10aChromatography, Thin Layer10aFatty Acids10aGlycolipids10aHumans10aleprosy10aLipids10aMice10aMycolic Acids10aNontuberculous Mycobacteria10aTuberculosis Vaccines1 aMederos L M1 aValdivia J A1 aValero-Guillén P L00aLipids of 'Mycobacterium habana', a synonym of Mycobacterium simiae with vaccine potential.  a324-90 v863 a<p>'Mycobacterium habana' was proposed as a distinct species within the genus Mycobacterium; however, it is actually a synonym of Mycobacterium simiae and included in the serotype I of this species. The potential use of 'M. habana' as a vaccine in both leprosy and tuberculosis has led to the analysis of its lipid composition in an attempt to define distinctive markers that could be used in the quality control of true strains of this bacterium. Lipids of taxonomic value (fatty and mycolic acids) are similar in 'M. habana' and M. simiae; nevertheless, they clearly differ on the basis of glycopeptidolipid (GPL) composition. Thus, contrary to M. simiae, most strains of 'M. habana' can be defined by the presence of three polar compounds, designated GPL-I, GPL-II and GPL-III, easily determined by thin-layer chromatography, and characterized, respectively, by the content of l-fucose, 2,4-di-O-Me-d-glucuronic acid, and 4-O-Me-d-glucuronic acid, as epitopes.</p>  a1472-9792